Results
1 -
10 of
25Munshi N C, Seitz D E, Fossella F, Lippman S M, Einhorn L H.
Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer., Investigational new drugs, Feb 1993 Guan X..
Glutathione and Mercapturic Acid Conjugates of Sulofenur and Their Activity against a Human Colon Cancer Cell Line, Drug Metabolism and Disposition, 2002 Ehlhardt W J.
Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human., Drug metabolism and disposition: the biological fate of chemicals, Jochheim Claudia M., Davis Margaret R., Baillie Kathleen M., Ehlhardt William J., Baillie Thomas A..
Glutathione-Dependent Metabolism of the Antitumor Agent Sulofenur. Evidence for the Formation ofp-Chlorophenyl Isocyanate as a Reactive Intermediate, Chemical Research in Toxicology, 2002 O'Brien Mary ER, Hardy Janet, Tan Sylvia, Walling Jackie, Peters Brian, Hatty Sarah, Wiltshaw Eve.
A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer, Cancer Chemotherapy and Pharmacology, 1992 Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: Report of three cases, Investigational New Drugs Diarylsulfonylureas : new anticancer agents with novel activities, toxicities and mechanism of action, Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy Antitumor diarylsulfonylureas: novel agents with unfulfilled promise, Investigational New Drugs A new anticancer agent (LY186641) interferes with creatinine assay, Cancer Chemotherapy and Pharmacology Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer, Cancer Chemotherapy and Pharmacology